Stanton Goldman

1.9k total citations
38 papers, 1.0k citations indexed

About

Stanton Goldman is a scholar working on Pathology and Forensic Medicine, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Stanton Goldman has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 14 papers in Genetics and 14 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Stanton Goldman's work include Lymphoma Diagnosis and Treatment (22 papers), Acute Lymphoblastic Leukemia research (12 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Stanton Goldman is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Acute Lymphoblastic Leukemia research (12 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Stanton Goldman collaborates with scholars based in United States, France and Australia. Stanton Goldman's co-authors include Mitchell S. Cairo, Lauren Harrison, Sherrie L. Perkins, Erin Morris, Susan G. Kreissman, John S. Holcenberg, F. Leonard Johnson, Conrad Tou, Jerry Z. Finklestein and Elizabeth Harvey and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Stanton Goldman

38 papers receiving 992 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stanton Goldman United States	16	443	382	359	311	226	38	1.0k
Felicitas Hitz Switzerland	17	669 1.5×	190 0.5×	560 1.6×	118 0.4×	151 0.7×	63	1.1k
Henning Bredenfeld Germany	14	556 1.3×	222 0.6×	380 1.1×	62 0.2×	66 0.3×	22	833
Alejandra Talavera Mexico	16	555 1.3×	116 0.3×	503 1.4×	79 0.3×	59 0.3×	50	867
Ami V. Desai United States	18	111 0.3×	229 0.6×	250 0.7×	80 0.3×	278 1.2×	52	1.0k
M Bertini Italy	16	586 1.3×	135 0.4×	379 1.1×	36 0.1×	135 0.6×	44	901
Alain Sadoun France	12	158 0.4×	173 0.5×	249 0.7×	56 0.2×	131 0.6×	28	820
Akthar Shamsaldin France	11	72 0.2×	216 0.6×	227 0.6×	180 0.6×	126 0.6×	11	768
P. Salvador United States	7	620 1.4×	171 0.4×	386 1.1×	47 0.2×	68 0.3×	7	840
H. Köppler Germany	19	297 0.7×	128 0.3×	382 1.1×	33 0.1×	104 0.5×	66	872
R. E. Marcus United Kingdom	18	1.1k 2.5×	156 0.4×	979 2.7×	61 0.2×	165 0.7×	47	1.9k

Countries citing papers authored by Stanton Goldman

Since Specialization

Citations

This map shows the geographic impact of Stanton Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanton Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanton Goldman more than expected).

Fields of papers citing papers by Stanton Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanton Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanton Goldman. The network helps show where Stanton Goldman may publish in the future.

Co-authorship network of co-authors of Stanton Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of Stanton Goldman. A scholar is included among the top collaborators of Stanton Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanton Goldman. Stanton Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldman, Stanton & Mitchell S. Cairo. (2023). Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults. Best Practice & Research Clinical Haematology. 36(2). 101463–101463. 5 indexed citations

Koduru, Prasad, Giovanni A. Botten, Jian Xu, et al.. (2020). Mixed Phenotype Acute Leukemia, B/Myeloid (Bilineal and Biphenotypic), With t(2;22)(q35;q12);EWSR1-FEV. Journal of Pediatric Hematology/Oncology. 43(3). e388–e394. 7 indexed citations

Audino, Anthony, Matthew J. Barth, Janet Ayello, et al.. (2019). Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. Blood. 134(Supplement_1). 3963–3963. 3 indexed citations

Cairo, Mitchell S., Anne Aupérin, Sherrie L. Perkins, et al.. (2018). Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. British Journal of Haematology. 182(6). 859–869. 37 indexed citations

Frazer, J. Kimble, Kevin J. Li, Paul J. Galardy, et al.. (2018). Excellent outcomes in children and adolescents with CNS⁺ Burkitt lymphoma or other mature B‐NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. British Journal of Haematology. 185(2). 374–377. 14 indexed citations

Chu, Yaya, Sanghoon Lee, Changhong Yin, et al.. (2018). Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. OncoImmunology. 8(1). e1512455–e1512455. 17 indexed citations

Day, Nancy S., Rodney R. Miles, Sherrie L. Perkins, et al.. (2017). Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. British Journal of Haematology. 177(4). 601–611. 12 indexed citations

Barth, Matthew J., Stanton Goldman, Lynette M. Smith, et al.. (2013). Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: A Children’s Oncology Group (COG) report.. Journal of Clinical Oncology. 31(15_suppl). 3055–3055. 1 indexed citations

Galardy, Paul J., Jessica Hochberg, Sherrie L. Perkins, et al.. (2013). Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B‐NHL: a Children's Oncology Group Report. British Journal of Haematology. 163(3). 365–372. 39 indexed citations

10.

Cairo, Mitchell S., Richard Sposto, Mary Gerrard, et al.. (2012). Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study. Journal of Clinical Oncology. 30(4). 387–393. 129 indexed citations

11.

Shiramizu, Bruce, Stanton Goldman, James C. Lynch, et al.. (2011). Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group report. British Journal of Haematology. 153(6). 758–763. 23 indexed citations

12.

Dhall, Girish, Juliane Grimm, Floyd H. Gilles, et al.. (2011). Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol.. Journal of Clinical Oncology. 29(15_suppl). 2011–2011. 27 indexed citations

13.

Cairo, Mitchell S., James C. Lynch, Lauren Harrison, et al.. (2010). Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.. Journal of Clinical Oncology. 28(15_suppl). 9536–9536. 12 indexed citations

14.

Candrilli, Sean D., Timothy Bell, William Irish, et al.. (2008). A Comparison of Inpatient Length of Stay and Costs Among Patients with Hematologic Malignancies (Excluding Hodgkin Disease) Associated with and Without Acute Renal Failure. Clinical Lymphoma & Myeloma. 8(1). 44–51. 41 indexed citations

15.

Cairo, Mitchell S., Virginia Davenport, Olga Bessmertny, et al.. (2004). Phase I/II dose escalation study of recombinant human interleukin‐11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study*. British Journal of Haematology. 128(1). 49–58. 22 indexed citations

16.

Goldman, Stanton. (2003). Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Review of Anticancer Therapy. 3(4). 429–433. 17 indexed citations

17.

Goldman, Stanton, Francisco Bracho, Virginia Davenport, et al.. (2001). Feasibility Study of IL-11 and Granulocyte Colony-Stimulating Factor After Myelosuppressive Chemotherapy to Mobilize Peripheral Blood Stem Cells From Heavily Pretreated Patients. The American journal of pediatric hematology/oncology. 23(5). 300–305. 11 indexed citations

18.

Goldman, Stanton, John S. Holcenberg, Jerry Z. Finklestein, et al.. (2001). A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 97(10). 2998–3003. 301 indexed citations

19.

Goldman, Stanton, Carmella van de Ven, Y Suen, et al.. (1999). Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplantation. 24(5). 535–544. 43 indexed citations

20.

Bracho, Francisco, Stanton Goldman, & Mitchell S. Cairo. (1998). Potential use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in neonates. Current Opinion in Hematology. 5(3). 215–220. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact